A leading Belgium-based company that offers personalized medicine to cancer patients, OncoDNA, has chosen to partner with N-of-One for interpretation of next-generation sequencing data of tumor samples.
N-of-One, Inc. , the leader in clinical interpretation for precision medicine in oncology, today announced an agreement with OncoDNA, the first company in Europe to provide personalized medicine in oncology based on the molecular analysis of each patient’s tumor. Under this agreement, N-of-One will provide the clinical interpretation for all of OncoDNA’s next-generation sequencing (NGS) and other molecular tests done for patients throughout Europe, the Middle East, and in other parts of the world. Financial terms of the agreement are not disclosed.
OncoDNA provides comprehensive tumor profiling services in order to assist medical doctors in their treatment choices and provide better monitoring of the evolution of patient tumors. The lab is led by a team of highly experienced experts in DNA sequencing and diagnostic analyses in oncology.
N-of-One’s clinical interpretation provides the relevant biological and clinical knowledge and insights related to the mutation profile of a tumor identified by sequencing linking this knowledge to relevant therapeutic strategies, including clinical trials.
Read the press release here: http://on.mktw.net/1lIkNTh
Source: MarketWatch
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More